** Shares of biotech company Renovaro Inc up 24.4% at $0.87
** David Weinstein appointed as RENB's director and CEO, succeeding Mark Dybul
** Co also names four new directors; board size increased to five members
** Realignment of resources to focus on RENB's AI platform, Renovaro Cube, which is used for multi-cancer early detection and patient monitoring
** Strategic review to also include pipeline prioritization and financial initiatives to strengthen co's balance sheet
** Up to last close, stock down ~73.35% YTD
(Reporting by Rishab Shaju in Bengaluru)
((Rishab.shaju@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。